Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Donald E Mager

Showing results (41-50 of 163) with videos related to

Pageof 17
Sort By:
Journal of Clinical Pharmacology|May 26, 2017
Influence of Meals and Glycemic Changes on QT Interval DynamicsBrenda Cirincione, Philip T Sager, Donald E Mager
The AAPS Journal|June 25, 2017
A Mechanism-Based PK/PD Model for Hematological Toxicities Induced by Antibody-Drug ConjugatesSihem Ait-Oudhia, Weiyan Zhang, Donald E Mager
The AAPS Journal|July 7, 2007
Partial derivative-based sensitivity analysis of models describing target-mediated drug dispositionAnson K Abraham, Wojciech Krzyzanski, Donald E Mager
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 16, 2003
Diversity of mechanism-based pharmacodynamic modelsDonald E Mager, Elzbieta Wyska, William J Jusko
The AAPS Journal|November 11, 2009
Comparison of two pharmacodynamic transduction models for the analysis of tumor therapeutic responses in model systemsJun Yang, Donald E Mager, Robert M Straubinger
Journal of Clinical Pharmacology|October 30, 2018
Population Pharmacokinetics of Tacrolimus in Transplant Recipients: What Did We Learn About Sources of Interindividual Variabilities?Olivia Campagne, Donald E Mager, Kathleen M Tornatore
Pharmaceutical Research|March 19, 2026
Binding Kinetics Can Explain Linear and Nonlinear Pharmacokinetics of Dipeptidyl Peptidase-IV Inhibitors Within a Single Target-Mediated FrameworkAdam Elalem, Mfonabasi E Ette, Donald E Mager
Pharmaceutical Research|March 18, 2005
Pharmacokinetics and pharmacodynamics of PEGylated IFN-beta 1a following subcutaneous administration in monkeysDonald E Mager, Berend Neuteboom, William J Jusko
Pharmaceutical Research|May 5, 2026
PK-PD Modeling Suggests Tumor Heterogeneity Limits Preclinical to Clinical Translation of Enzalutamide in Prostate CancerSe Jin Kim, Robert Bies, Donald E Mager
Pharmaceutical Research|May 17, 2012
Meta-analysis of nanoparticulate paclitaxel delivery system pharmacokinetics and model prediction of associated neutropeniaSihem Ait-Oudhia, Robert M Straubinger, Donald E Mager
Pageof 17

Showing results (41-50 of 163) with videos related to

Sort By:
Pageof 17
Journal of Clinical Pharmacology|May 26, 2017
Influence of Meals and Glycemic Changes on QT Interval DynamicsBrenda Cirincione, Philip T Sager, Donald E Mager
The AAPS Journal|June 25, 2017
A Mechanism-Based PK/PD Model for Hematological Toxicities Induced by Antibody-Drug ConjugatesSihem Ait-Oudhia, Weiyan Zhang, Donald E Mager
The AAPS Journal|July 7, 2007
Partial derivative-based sensitivity analysis of models describing target-mediated drug dispositionAnson K Abraham, Wojciech Krzyzanski, Donald E Mager
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 16, 2003
Diversity of mechanism-based pharmacodynamic modelsDonald E Mager, Elzbieta Wyska, William J Jusko
The AAPS Journal|November 11, 2009
Comparison of two pharmacodynamic transduction models for the analysis of tumor therapeutic responses in model systemsJun Yang, Donald E Mager, Robert M Straubinger
Journal of Clinical Pharmacology|October 30, 2018
Population Pharmacokinetics of Tacrolimus in Transplant Recipients: What Did We Learn About Sources of Interindividual Variabilities?Olivia Campagne, Donald E Mager, Kathleen M Tornatore
Pharmaceutical Research|March 19, 2026
Binding Kinetics Can Explain Linear and Nonlinear Pharmacokinetics of Dipeptidyl Peptidase-IV Inhibitors Within a Single Target-Mediated FrameworkAdam Elalem, Mfonabasi E Ette, Donald E Mager
Pharmaceutical Research|March 18, 2005
Pharmacokinetics and pharmacodynamics of PEGylated IFN-beta 1a following subcutaneous administration in monkeysDonald E Mager, Berend Neuteboom, William J Jusko
Pharmaceutical Research|May 5, 2026
PK-PD Modeling Suggests Tumor Heterogeneity Limits Preclinical to Clinical Translation of Enzalutamide in Prostate CancerSe Jin Kim, Robert Bies, Donald E Mager
Pharmaceutical Research|May 17, 2012
Meta-analysis of nanoparticulate paclitaxel delivery system pharmacokinetics and model prediction of associated neutropeniaSihem Ait-Oudhia, Robert M Straubinger, Donald E Mager
Pageof 17